Jether Amos Espinosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jether Amos Espinosa has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Diane S. Krause
Yale University, School of Medicine
3 shared publications - Madeline Y. Mayday
Yale University, School of Medicine
3 shared publications - Gina Lee
Yale Stem Cell Center
2 shared publications Lin Wang
Yale University, School of Medicine
2 shared publications- Abigail Rich
Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, USA
1 shared publication Andreas P. Pintado-Urbanc
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT
1 shared publication
Latest Publications
- Open Access
RBM15::MKL1 uncouples SPOC-dependent m6A remodeling from WTAP recruitment
The recurrent t(1;22) translocation associated with pediatric acute megakaryoblastic leukemia generates the RBM15::MKL1 (RM) fusion protein that retains the RNA-binding and SPOC domains of RBM15. RBM15 recruits the N6-methyladenosine (m6A) methyltransferase complex (MTC), of which WTAP is a key regulatory component. How RM engages this machinery and whether the SPOC domain is required for its leukemogenic activity remain unclear. Here, we investigated the molecular determinants of WTAP recruitment by RBM15 and RM and their contribution to RM-mediated disruption of megakaryocyte differentiation. Structure-guided mutagenesis identified a conserved basic surface within the isolated RBM15 SPOC domain that is required for WTAP association. Unexpectedly, disruption of this surface or complete SPOC deletion failed to abolish WTAP association with full-length RBM15 or RM, indicating that additional determinants mediate MTC recruitment. In human erythroleukemia cells, RM impaired TPA-induced megakaryocytic maturation, as assessed by differentiation markers, polyploidization, and morphology; this blockade persisted following SPOC disruption. However, transcriptomic analysis demonstrated that RM lacking the SPOC domain elicited an attenuated gene expression response compared with unmutated RM, including alterations in WNT/Beta-catenin-associated genes. m6A-enriched RNA profiling further revealed extensive remodeling of the m6A epitranscriptome by RM, while SPOC deletion shifted RM-associated m6A changes toward a more wild-type-like state. Together, these findings demonstrate that although the SPOC domain contributes to RM-mediated molecular regulation, it is dispensable for stable MTC association and maintenance of the differentiation blockade, revealing previously unrecognized redundancy in RBM15-mediated recruitment of the m6A machinery.
Open AccessRBM15::MKL1 uncouples SPOC-dependent m6A remodeling from WTAP recruitment
The recurrent t(1;22) translocation associated with pediatric acute megakaryoblastic leukemia generates the RBM15::MKL1 (RM) fusion protein that retains the RNA-binding and SPOC domains of RBM15. RBM15 recruits the N6-methyladenosine (m6A) methyltransferase complex (MTC), of which WTAP is a key regulatory component. How RM engages this machinery and whether the SPOC domain is required for its leukemogenic activity remain unclear. Here, we investigated the molecular determinants of WTAP recruitment by RBM15 and RM and their contribution to RM-mediated disruption of megakaryocyte differentiation. Structure-guided mutagenesis identified a conserved basic surface within the isolated RBM15 SPOC domain that is required for WTAP association. Unexpectedly, disruption of this surface or complete SPOC deletion failed to abolish WTAP association with full-length RBM15 or RM, indicating that additional determinants mediate MTC recruitment. In human erythroleukemia cells, RM impaired TPA-induced megakaryocytic maturation, as assessed by differentiation markers, polyploidization, and morphology; this blockade persisted following SPOC disruption. However, transcriptomic analysis demonstrated that RM lacking the SPOC domain elicited an attenuated gene expression response compared with unmutated RM, including alterations in WNT/Beta-catenin-associated genes. m6A-enriched RNA profiling further revealed extensive remodeling of the m6A epitranscriptome by RM, while SPOC deletion shifted RM-associated m6A changes toward a more wild-type-like state. Together, these findings demonstrate that although the SPOC domain contributes to RM-mediated molecular regulation, it is dispensable for stable MTC association and maintenance of the differentiation blockade, revealing previously unrecognized redundancy in RBM15-mediated recruitment of the m6A machinery.
- 2 September 2026
- Published by Elsevier in Trends in Cancer
RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis
- 2 September 2026
- Published by Elsevier in Trends in Cancer
RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis
- 28 August 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (9) , 1096-1109
RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation
The recurrent t(1;22) translocation in acute megakaryoblastic leukemia (AMKL) encodes the RBM15-MKL1 fusion protein. Dysregulation of the N6-methyladenosine (m6A) modification affects RNA fate and is linked to oncogenesis. Because RBM15 is critical for bringing the m6A writer complex to specific RNAs, we hypothesized that RM disrupts the m6A modification, thereby altering the RNA fate to drive leukemogenesis in RM-AMKL. Using a multiomics approach, we showed for the first time, to our knowledge, that RM retains the RNA-binding and m6A-modifying functions of RBM15 while also selectively regulating distinct messenger RNA targets, including Frizzled genes, in the Wnt signaling pathway. Treating murine RM-AMKL cells with the methyltransferase 3 (METTL3) inhibitor STM3675, which decreases m6A deposition, induced apoptosis in vitro and prolonged survival in transplanted mice. Frizzled genes were upregulated by RM and downregulated upon METTL3 inhibition, implicating an m6A-dependent mechanism in their dysregulation. Direct Frizzled knockdown reduced RM-AMKL growth in vitro and in vivo, highlighting Wnt signaling as a key oncogenic driver. Elevated Wnt pathway activity and Frizzled expression in multiple forms of human AMKL underscores the relevance of our findings. Together, our results establish that RM-specific m6A modifications and Wnt pathway activation are critical drivers of RM-AMKL, thereby identifying these pathways as potential therapeutic targets.
- 28 August 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (9) , 1096-1109
RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation
The recurrent t(1;22) translocation in acute megakaryoblastic leukemia (AMKL) encodes the RBM15-MKL1 fusion protein. Dysregulation of the N6-methyladenosine (m6A) modification affects RNA fate and is linked to oncogenesis. Because RBM15 is critical for bringing the m6A writer complex to specific RNAs, we hypothesized that RM disrupts the m6A modification, thereby altering the RNA fate to drive leukemogenesis in RM-AMKL. Using a multiomics approach, we showed for the first time, to our knowledge, that RM retains the RNA-binding and m6A-modifying functions of RBM15 while also selectively regulating distinct messenger RNA targets, including Frizzled genes, in the Wnt signaling pathway. Treating murine RM-AMKL cells with the methyltransferase 3 (METTL3) inhibitor STM3675, which decreases m6A deposition, induced apoptosis in vitro and prolonged survival in transplanted mice. Frizzled genes were upregulated by RM and downregulated upon METTL3 inhibition, implicating an m6A-dependent mechanism in their dysregulation. Direct Frizzled knockdown reduced RM-AMKL growth in vitro and in vivo, highlighting Wnt signaling as a key oncogenic driver. Elevated Wnt pathway activity and Frizzled expression in multiple forms of human AMKL underscores the relevance of our findings. Together, our results establish that RM-specific m6A modifications and Wnt pathway activation are critical drivers of RM-AMKL, thereby identifying these pathways as potential therapeutic targets.
- 17 February 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (3) , 320-337
Reimagining dots and dashes: Visualizing structure and function of organelles for high-content imaging analysis
- 17 February 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (3) , 320-337
Reimagining dots and dashes: Visualizing structure and function of organelles for high-content imaging analysis